Results of Prospective Cohort Study on Symptomatic Cerebrovascular Occlusive Disease Showing Mild Hemodynamic Compromise [Japanese Extracranial-Intracranial Bypass Trial (JET)-2 Study]

Hiroharu Kataoka,1 Susumu Miyamoto,2 Kuniaki Ogasawara,3 Koji Ihara,4 Jun C. Takahashi,1 Jyoji Nakagawara,5 Tooru Inoue,6 Etsuro Mori,7 Akira Ogawa;3 On Behalf of the JET-2 Investigators

1Department of Neurosurgery, National Cerebral and Cardiovascular Center, Suita, Osaka; 2Department of Neurosurgery, Kyoto University, Graduate School of Medicine, Kyoto, Kyoto; 3Department of Neurosurgery, Iwate Medical University, School of Medicine, Morioka, Iwate; 4Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka; 5Integrative Stroke Imaging Center, National Cerebral and Cardiovascular Center, Suita, Osaka; 6Department of Neurosurgery, Fukuoka University, Fukuoka, Fukuoka; 7Department of Behavioral Neurology and Cognitive Neuroscience, Tohoku University Graduate School of Medicine, Sendai, Miyagi

Abstract

The purpose of this study is to determine the true threshold of cerebral blood flow (CBF) and cerebrovascular reactivity (CVR) for subsequent ischemic stroke without extracranial-intracranial (EC-IC) bypass surgery in patients with hemodynamic ischemia due to symptomatic major cerebral arterial occlusive diseases. Patients were categorized based on rest CBF and CVR into four subgroups as follows: Group A, 80% < CBF < 90% and CVR < 10%; Group B, CBF < 80% and 10% < CVR < 20%; Group C, 80% < CBF < 90% and 10% < CVR < 20%; and Group D, CBF < 90% and 20% < CVR < 30%. Patients were followed up for 2 years under best medical treatment by the stroke neurologists. Primary and secondary end points were defined as all adverse events and ipsilateral stroke recurrence respectively. A total of 132 patients were enrolled. All adverse events were observed in 9 patients (3.5%/year) and ipsilateral stroke recurrence was observed only in 2 patients (0.8%/year). There was no significant difference among the four subgroups in terms of the rate of both primary and secondary end points. Compared with the medical arm of the Japanese EC-IC bypass trial (JET) study including patients with CBF < 80% and CVR < 10% as a historical control, the incidence of ipsilateral stroke recurrence was significantly lower in the present study. Patients with symptomatic major cerebral arterial occlusive diseases and mild hemodynamic compromise have a good prognosis under medical treatment. EC-IC bypass surgery is unlikely to benefit patients with CBF > 80% or CVR > 10%.

Key words: hemodynamic cerebral ischemia, stroke, recurrence, cerebral blood flow, cerebrovascular reactivity

Introduction

Patients with symptomatic major cerebral arterial occlusion or stenosis have a substantial risk of recurrent ischemic stroke.1–3 A growing body of evidence is accumulating to show that patients with a compromised cerebral blood flow (CBF) have a high risk of ischemic stroke.4–8 Single photon emission computed tomography (SPECT) combined with acetazolamide challenge enables us to measure CBF and cerebrovascular reactivity (CVR), which represent the degree of hemodynamic failure.
Decreased CBF and CVR are proven predictors of increased risk for subsequent stroke in patients with symptomatic major cerebral arterial occlusive diseases when treated medically. On the other hand, extracranial-intracranial (EC-IC) bypass surgery improves impaired cerebral hemodynamics. On the assumption that EC-IC bypass surgery prevents further ischemic stroke in high risk subgroups of patients with symptomatic major cerebral arterial occlusive diseases, Japanese EC-IC bypass trial (JET study) was conducted as a prospective randomized multicenter study, and demonstrated the effect of EC-IC bypass surgery in preventing subsequent cerebral ischemia in highly selected patients. In the JET study, the recurrence rate of ipsilateral stroke in medically treated patients was not different between the moderate ischemia subgroup (0% < CVR < 10%) and the severe ischemia subgroup (CVR < 0%), suggesting that the threshold of hemodynamic compromise beneath which the risk of stroke recurrence increases when treated medically may be milder than initially assumed threshold (CBF < 80% and CVR < 10%). To determine the true threshold of CBF and CVR for subsequent ischemic stroke without EC-IC bypass surgery, JET-2 study was planned. In the JET-2 study, patients with symptomatic major cerebral arterial occlusive diseases in the anterior circulation and mild compromised cerebral hemodynamics were enrolled, divided into four groups, treated medically and prospectively followed up for 2 years.

Materials and Methods

I. Patient eligibility

This study is a multicenter prospective cohort study to examine the incidence of stroke recurrence, disability, and death of medically treated patients with symptomatic occlusive diseases of the anterior circulation. The target was patients with occlusion or severe stenosis of the middle cerebral artery (MCA) or the internal carotid artery (ICA) with mild-to-moderate hemodynamic failure who experienced transient ischemic attacks (TIAs) or non-disabling strokes within 6 months derived from the hemisphere ipsilateral to the lesion. Table 1 lists all the inclusion and exclusion criteria. The present study was approved by local ethics committees of all participant institutes. Written informed consent was obtained from all patients.

II. Measurements of CBF and CVR

Regional CBF was quantitatively measured more than 3 weeks after the last ischemic attacks using positron emission tomography (PET), $^{133}$Xe inhalation method and SPECT, $^{133}$Xe-enhanced computed tomography (Xe-CT), or N-isopropyl-p-[($^{123}$I])iodoamphetamine ($^{123}$I-IMP) SPECT. Regional CBF was measured with and without the injection of 17 mg/kg iv acetazolamide. In $^{123}$I-IMP SPECT with acetazolamide challenge, $^{123}$I-IMP was administered 7–10 min after injection of acetazolamide and SPECT acquisition was started 15–20 min after $^{123}$I-IMP injection. $^{123}$I-IMP SPECT with acetazolamide challenge was performed within a week of the measurement of rest CBF. In other methods, tracers were administered 15–20 min after injection of acetazolamide. The region of interest (ROI) was designated manually in the cerebral cortex in the territory of ipsilateral MCA at the level of the anterior horn of the lateral ventricle. ROIs were

| Table 1 | Patient eligibility for the JET-2 study |
|---------|--------------------------------------|
| Inclusion criteria | Clinical requirements |
| 1. Age under 73 years at the time of registration |
| 2. Independent of daily life (modified Rankin disability scale score of 0–2) |
| Radiological requirements |
| 1. CT/MRI |
| Lack of large infarction spread widely over the territory of a main arterial trunk |
| Lack of contrast enhancement in the infarcted area |
| 2. Angiography |
| Occlusion or severe stenosis in the main trunk of the middle cerebral artery or the internal carotid artery (except for candidates for carotid endarterectomy) |
| 3. SPECT/PET |
| 80% of normal value < CBF < 90% of normal value or 10% < CVR < 30% |
| Exclusion criteria |
| 1. Not independent in daily life (modified Rankin disability scale score of 3–5) |
| 2. Major cerebral arterial occlusive lesions due to diseases other than atherosclerosis |
| 3. Malignant tumors or organ failure of the heart, liver, kidney, or lung |
| 4. Myocardial infarction within the past 6 months |
| 5. Uncontrolled diabetes mellitus showing a serum fasting blood glucose level > 300 mg/dL, or requires insulin |
| 6. Hypertension with a diastolic blood pressure of > 110 mmHg |
| 7. Artery to artery embolism |
| 8. Cardioembolism |

CBF: cerebral blood flow, CT: computed tomography, CVR: cerebrovascular reactivity, JET: Japanese extracranial-intracranial bypass trial, MRI: magnetic resonance imaging, PET: positron emission tomography, SPECT: single photon emission computed tomography.
also placed in bilateral cerebellar hemispheres and in the contralateral MCA territory as reference. Regional CBF was expressed as relative values (%) to normal control values of each institute obtained from volunteers free of cerebrovascular disease. CVR was calculated as follows: CVR (%) = [(acetazolamide challenge CBF – rest CBF)/rest CBF] × 100.

All patients were divided into four groups according to rest CBF (CBF) and CVR as follows: A: 80% < CBF < 90%, CVR < 10%; B: CBF < 80%, 10% < CVR < 20%; C: 80% < CBF < 90%, 10% < CVR < 20%; D: CBF < 90%, 20% < CVR < 30% (Fig. 1).

III. Patient follow-up

Each patient was followed up for 2 years after enrollment by a pair of a neurologist and a neurosurgeon in each participating institute. Neurological findings, computed tomography (CT)/magnetic resonance imaging (MRI), and CBF/CVR measurements were examined and reported at the time of enrollment and 6 months, 1 year, and 2 years after enrollment. Evaluation of the cognitive function and angiography were performed at the time of enrollment and 2 years after enrollment.

IV. End points

The following items constitute primary end points: (1) completed stroke causing significant morbidity (modified Rankin disability scale score of 3–5), (2) vascular death, (3) significant morbidity and mortality from other causes, and (4) requirement of EC-IC bypass as determined by a registered neurologist. The following items constitute secondary end points: (1) ipsilateral completed stroke causing significant morbidity (modified Rankin disability scale score of 3–5) and (2) death associated with ipsilateral completed stroke.

V. Comparison with data of the medical arm of the JET study as a historical control

JET study is a prospective multicenter trial to determine that EC-IC bypass surgery can prevent stroke recurrence of patients with major cerebral artery occlusive diseases and severe hemodynamic ischemia. The medical arm of JET study consists of patients enrolled according to the same inclusion and exclusion criteria except for the values of CBF and CVR, and randomized to the medically treated group. The inclusion criteria for hemodynamic compromise of the JET study was CBF < 80% and CVR < 10%. The rate of patients reaching the end points and length of time without end points were compared between the medical arm of the JET study and the JET-2 study. Primary end points were the same between the two studies. But the secondary
The primary end point of the JET study included requirement of EC-IC bypass as determined by a registered neurologist in addition to ipsilateral completed stroke causing significant morbidity (modified Rankin disability scale score of 3–5). Therefore, concerning the rate of the ipsilateral stroke recurrence, we compared these two studies according to the secondary end point of the JET study.

VI. Statistical analysis

One-way analysis of variance (ANOVA) and χ² for independence test were used to compare baseline characteristics of the four groups. The length of time without an adverse event was compared between groups with the Kaplan-Meier method and log-rank statistics. The data were analyzed using a univariate Cox regression model to determine which risk factors had significant associations with the adverse events. Age, sex, complications (hypertension, diabetes mellitus, hypercholesterolemia, prior myocardial infarction), entry event, side of the lesion, responsible lesion, and CBF classification were considered covariates. When some covariates were shown to be a significant predictor of end points, multivariate analysis was performed using stepwise selection with a P value of 0.10 for backward elimination to select the best predictive model. All analyses were performed with IBM SPSS software, version 22 (IBM Software Group, Chicago, Illinois, USA). A value of P < 0.05 was considered statistically significant.

Table 2 Baseline characteristics

|                    | Group A (n = 18) | Group B (n = 30) | Group C (n = 26) | Group D (n = 54) | P value |
|--------------------|-----------------|-----------------|-----------------|-----------------|---------|
| Age, yr (mean ± SD)| 64.1 ± 6.7      | 62.4 ± 8.4      | 58.2 ± 11.5     | 60.9 ± 9.3      | 0.19    |
| Male               | 14 (77.8%)      | 27 (90%)        | 22 (84.6%)      | 43 (79.6%)      | 0.6     |
| Hypertension       | 9 (50%)         | 19 (63.3%)      | 10 (38.5%)      | 32 (59.3%)      | 0.23    |
| Diabetes           | 6 (33.3%)       | 6 (20%)         | 5 (19.3%)       | 14 (25.9%)      | 0.67    |
| Hypercholesterolemia| 7 (38.9%)      | 8 (26.7%)       | 6 (23.1%)       | 10 (18.5%)      | 0.36    |
| Prior MI           | 1 (5.6%)        | 2 (6.7%)        | 2 (7.7%)        | 5 (9.3%)        | 0.95    |
| Prior stroke       | 1 (5.6%)        | 2 (6.7%)        | 1 (3.9%)        | 2 (3.7%)        | 0.93    |
| Entry event type   |                 |                 |                 |                 |         |
| transient ischemic attack | 11 (61.1%) | 16 (53.3%) | 12 (46.2%) | 26 (48.2%) | 0.75 |
| completed stroke   | 7 (38.9%)       | 14 (46.7%)      | 14 (53.9%)      | 28 (51.9%)      |         |
| Entry event side   |                 |                 |                 |                 |         |
| right              | 8 (44.4%)       | 15 (50%)        | 9 (34.6%)       | 28 (51.9%)      | 0.52    |
| left               | 10 (55.6%)      | 15 (50%)        | 17 (65.4%)      | 26 (48.2%)      |         |
| Responsible lesion for entry event |            |                 |                 |                 |         |
| ICA                | 10 (55.6%)      | 17 (56.7%)      | 16 (61.5%)      | 36 (66.7%)      | 0.76    |
| MCA                | 8 (44.4%)       | 13 (43.3%)      | 10 (38.5%)      | 18 (33.3%)      |         |

ICA: internal carotid artery, MCA: middle cerebral artery, MI: myocardial infarction, SD: standard deviation, yr: year.

A total of 132 patients were enrolled in the JET-2 study between January 2002 and March 2007. Eighteen patients were classified into group A, 32 into group B, 26 into group C, and 56 into group D. The means of CBF and CVR in each group are listed in Fig. 1. Two patients of group B and 2 patients of group D were dropped out from the follow-up. Therefore, 128 patients were followed up until end points occurred or for 2 years after enrollment if no event occurred. Table 2 summarizes the baseline characteristics of patients. No variables at entry in the study differed significantly among the four groups.

The primary end point was observed in 3 (16.7%) in Group A, in 2 (6.7%) in Group B, in 3 (11.5%) in Group C, and 1 (1.9%) in Group D (Table 3). Of these, only 2 patients [1 (5.6%) in Group A and 1 (3.3%) in Group B] experienced recurrence of ipsilateral stroke (Table 3). Other primary end points observed were as follows: 3 patients died of cardiac diseases (1 in Group A, 1 in Group C, and 1 in Group D), 1 died of cancer (in Group C), and 3 patients underwent EC-IC bypass determined by neurologists (1 in Group A, 1 in Group B, and 1 in Group C). The rates of the primary end point and the secondary end point did not differ among the four groups (P = 0.13 for the primary end point, P = 0.29 for the secondary end point, χ² test). Cox regression analysis revealed that the hazard ratios
of Group A to Group D were 1.22 (95% confidence interval, 0.68–2.08) as to the primary end point and 1.07 (95% confidence interval, 0.60–1.83) as to the secondary end point. Kaplan-Meier analysis and the log-rank test also showed the cumulative event-free survival rate was not different among the four groups (P = 0.15 for the primary end point, P = 0.30 for the secondary end point) (data not shown). Univariate Cox regression analysis showed that no risk factors including CBF classification selected as covariates were significant (Table 4). Thus, multivariate analysis was not performed.

In the medical arm of the JET study, the primary end point was observed in 17 (16.6%) and secondary end point (including ipsilateral stroke recurrence and bypass surgery determined by neurologists) was observed in 11 (10.7%) (Table 5), which were significantly higher than those in patients enrolled in the JET-2 study (P = 0.02 for the primary end point, P = 0.04 for the secondary end point, χ² test). Fig. 2 shows the Kaplan-Meier survival curves for the primary and secondary end points of the medical arm of the JET study and the JET-2 study. The log-rank test revealed that the JET group was at significantly higher risk than the JET-2 group for both the primary end point (P = 0.02) and the secondary end point (P = 0.04).

### Discussion

The present study demonstrated that patients with major cerebral arterial occlusive diseases showing mild hemodynamic compromise carry a relatively low risk of stroke recurrence. The overall rate of ipsilateral stroke recurrence was 0.8%/year and distinctly lower than that in the medical arm of the JET study. In the JET-2 study, patients were divided into four groups according to the severity of CBF in order to find the threshold of CBF and CVR for stroke recurrence. However, because of the low rate of vascular events in all groups, there was no significant difference among the groups in terms of end point rates and an event-free survival rate. Instead, the rates of both adverse events (primary end point) and recurrence of ipsilateral stroke including EC-IC bypass surgery determined by neurologists (secondary

### Table 3 End point rate

|                  | Group A (n = 18) | Group B (n = 30) | Group C (n = 26) | Group D (n = 54) | P value |
|------------------|-----------------|-----------------|-----------------|-----------------|--------|
| **Primary end point** |                 |                 |                 |                 |        |
| Stroke           | 3 (16.7%)       | 2 (6.7%)        | 3 (11.5%)       | 1 (1.9%)        | 0.13   |
| Death            | 1               | 1               | 2               | 1               |        |
| EC-IC bypass     | 1               | 1               | 1               |                 |        |
| **Secondary end point** |               |                 |                 |                 | 0.29   |
| Stroke           | 1 (5.6%)        | 1 (3.3%)        | 0               | 0               |        |

EC-IC: extracranial-intracranial.

### Table 4 Univariate Cox regression analysis of risk factors for the primary end point

|                      | Primary end point | Hazard ratio | 95% CI       | P value |
|----------------------|-------------------|--------------|--------------|---------|
| Age > 65 yr          | 1.91              | 0.50–7.70    | 0.33         |
| Male                 | 1.68              | 0.31–31.2    | 0.6          |
| Hypertension         | 0.64              | 0.16–2.43    | 0.51         |
| Diabetes             | 1.56              | 0.33–5.91    | 0.54         |
| Hypercholesterolemia | 0.87              | 0.13–3.61    | 0.86         |
| Prior MI             | 3.6               | 0.54–14.9    | 0.16         |
| Entry event type     |                   |              |              |         |
| TIA                  | 1.22              | 0.32–4.92    | 0.77         |
| Entry event side     |                   |              |              |         |
| Right                | 1.4               | 0.37–5.64    | 0.62         |
| Responsible lesion for entry event | | | | |
| ICA                  | 2.17              | 0.52–14.6    | 0.3          |
| CBF classification (to Group D)* | | | | |
| Group A              | 9.29              | 0.97–89.3    | 0.054        |
| Group B              | 3.73              | 0.67–61.5    | 0.28         |
| Group C              | 6.39              | 0.68–1.81    | 0.11         |

*Group D was considered as a reference. CI: confidence interval, ICA: internal carotid artery, MI: myocardial infarction, TIA: transient ischemic attack.

### Table 5 End point rate (JET vs. JET-2)

|                      | JET-2 (n = 128) | Medical arm of JET (n = 103) | P value |
|----------------------|-----------------|-----------------------------|---------|
| **Primary end point** |                 |                             |         |
| any stroke           | 9 (7.0%)        | 17 (16.6%)                  | 0.02    |
| Death                | 4               | 2                           |         |
| MI                   | 2               | 2                           |         |
| EC-IC bypass         | 3               | 4                           |         |
| **Secondary end point** |               |                             | 0.04    |
| Ipsilateral stroke   | 2               | 7                           |         |
| EC-IC bypass         | 3               | 4                           |         |

JET: Japanese extracranial-intracranial bypass trial, EC-IC: extracranial-intracranial, MI: myocardial infarction.
end point) were significantly higher in the medical arm of the JET study than those in patients enrolled in the JET-2 study. Inclusion criteria and exclusion criteria in these two groups were identical except for values of rest CBF and CVR at the entry, and patients in both groups were followed up for 2 years receiving medical treatment. Therefore, these results suggest that “rest CBF < 80% and CVR < 10%” is the threshold of hemodynamic compromise beneath which the risk of stroke recurrence increases in patients with symptomatic major arterial occlusive diseases, if treated medically.

The hemodynamic status of an occlusive disease has been categorized into three stages. Stage 0 represents normal cerebral hemodynamics. Stenosis or occlusion of major cerebral arteries can cause a reduction in the perfusion pressure in their vascular territories if collaterals are not adequate. At first, autoregulatory vasodilation maintains normal CBF (Stage 1 hemodynamic ischemia). When perfusion pressure decreases further, CBF begins to decrease, and the brain tissue increases oxygen extraction fraction (OEF) to maintain cerebral oxygen metabolism and function (Stage 2 hemodynamic ischemia). Previous prospective studies demonstrated that increased OEF on PET is predicative of recurrent ischemic stroke in symptomatic major cerebral arterial occlusive diseases. Although PET has the advantage of being able to directly detect stage 2 hemodynamic ischemia, its clinical availability is limited by high cost and complexity. Diminished vascular reactivity in response to acetazolamide challenge with reduced rest CBF quantified by SPECT is also proven independent predictors of increased risk for stroke recurrence in patients with symptomatic major cerebral arterial occlusive diseases. Several previous reports stated the correlation between compromised CVR and high OEF. Pindzola et al. reported that CVR was able to identify all regions with elevated OEF at a CVR threshold of 10%, showing significant agreement with the CVR threshold derived from the JET and JET-2 study.

EC-IC bypass surgery can restore the perfusion pressure in the area of stage 2 hemodynamic ischemia and has been expected to have the preventive effect on stroke recurrence in patients with cerebral arterial occlusive diseases. The JET study demonstrated, for the first time, the preventive effect of EC-IC bypass on stroke recurrence in selected patients (rest CBF < 80% and CVR < 10%). Based on the result of a subgroup analysis in the JET study showing that the recurrence rate of ipsilateral stroke in medically treated patients was not different between the moderate ischemia subgroup (0% < CVR < 10%) and the severe ischemia subgroup (CVR < 0%), the JET-2 study was planned to identify the true threshold of CBF and CVR for the selection of patients who are benefited from EC-IC bypass surgery. Initially, the threshold was assumed to exist in the range of hemodynamic ischemia milder than JET study inclusion criteria. However, results of the JET-2 study strongly suggested that the CBF threshold of inclusion criteria of the JET study was the true threshold of the surgical indication of EC-IC bypass surgery. The preventive effect of EC-IC bypass surgery on stroke recurrence is still controversial, because carotid surgery occlusion...
The JET-2 study revealed a good prognosis of major cerebral arterial occlusive diseases showing mild hemodynamic compromise. The rate of stroke recurrence in medically treated patients increased if rest CBF was less than 80% of a normal value and CVR was less than 10%. EC-IC bypass surgery is unlikely to benefit patients with rest CBF > 80% or CVR > 10%.

Acknowledgments

This study was supported by research grants cardiovascular diseases (16C-13 and 18C-22) from the Ministry of Health, Labor, and Welfare of Japan.

Clinical trial registration: http://www.umin.ac.jp/ctr/index.htm. Unique identifier: C000000171

Conflicts of Interest Disclosure

The authors report no conflicts of interest relevant to the research. All authors who are members of The Japan Neurosurgical Society have registered online Self-reported COI Disclosure Statement Form.

References

1) Klijn CJ, van Buren PA, Kappelle LJ, Tulleken CA, Eikelboom BC, Algra A, van Gijn J: Outcome in patients with symptomatic occlusion of the internal carotid artery. Eur J Vasc Endovasc Surg 19: 579–586, 2000
2) Persoon S, Luitse MJ, de Borst GJ, van der Zwan A, Algra A, Kappelle LJ, Klijn CJ: Symptomatic internal carotid artery occlusion: a long-term follow-up study. J Neurol Neurosurg Psychiatry 82: 521–526, 2011
3) Flaherty ML, Flemming KD, McClelland R, Jorgensen NW, Brown RD: Population-based study of symptomatic internal carotid artery occlusion: incidence and long-term follow-up. Stroke 35: e349–e352, 2004
4) Grubb RL, Derdeyn CP, Fritsch SM, Carpenter DA, Yundt KD, Videen TO, Spitznagel EL, Powers WJ: Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion. JAMA 280: 1055–1060, 1998
5) Yamauchi H, Fukuyama H, Nagahama Y, Nabatame H, Ueno M, Nishizawa S, Konishi J, Shio H: Significance of increased oxygen extraction fraction in five-year prognosis of major cerebral arterial occlusive diseases. J Nucl Med 40: 1992–1998, 1999
6) Ogawara K, Ogawa A, Yoshimoto T: Cerebrovascular reactivity to acetazolamide and outcome in patients with symptomatic internal carotid or middle cerebral artery occlusion: a xenon-133 single-photon emission computed tomography study. Stroke 33: 1857–1862, 2002
7) Kuroda S, Houkin K, Kamiyama H, Mitsumori K, Iwasaki Y, Abe H: Long-term prognosis of medically treated patients with internal carotid or middle cerebral artery occlusion: can acetazolamide test predict it? Stroke 32: 2110–2116, 2001
8) Webster MW, Makaroun MS, Steed DL, Smith HA, Johnson DW, Yonas H: Compromised cerebral blood flow reactivity is a predictor of stroke in patients with symptomatic carotid artery occlusive disease. J Vasc Surg 21: 338–344; discussion 344–345, 1995
9) Nemoto EM, Yonas H, Kuwabara H, Pindzola RR, Sashin D, Meltzer CC, Price JC, Chang Y, Johnson DW: Identification of hemodynamic compromise by cerebrovascular reserve and oxygen extraction fraction in occlusive vascular disease. J Cereb Blood Flow Metab 24: 1081–1089, 2004
10) Yonas H, Smith HA, Durham SR, Pentheny SL, Johnson DW: Increased stroke risk predicted by compromised cerebral blood flow reactivity. J Neurosurg 79: 483–489, 1993

Neurol Med Chir (Tokyo) 55, June, 2015
11) Schmiedek P, Piepgras A, Leinsinger G, Kirsch CM, Einhupl K: Improvement of cerebrovascular reserve capacity by EC-IC arterial bypass surgery in patients with ICA occlusion and hemodynamic cerebral ischemia. *J Neurosurg* 81: 236–244, 1994

12) Baron JC, Bousser MG, Rey A, Guillard A, Comar D, Castaigne P: Reversal of focal “misery-perfusion syndrome” by extra-intracranial arterial bypass in hemodynamic cerebral ischemia. A case study with 15O positron emission tomography. *Stroke* 12: 454–459, 1981

13) JET Study Group: Japanese EC-IC bypass trial (JET study): the second interim analysis. *Surg Cereb Stroke* 30: 434–437, 2002

14) Derdeyn CP, Grubb RL, Powers WJ: Cerebral hemodynamic impairment: methods of measurement and association with stroke risk. *Neurology* 53: 251–259, 1999

15) Nariai T, Suzuki R, Hirakawa K, Maehara T, Ishii K, Senda M: Vascular reserve in chronic cerebral ischemia measured by the acetazolamide challenge test: comparison with positron emission tomography. *AJNR Am J Neuroradiol* 16: 563–570, 1995

16) Herold S, Brown MM, Frackowiak RS, Mansfield AO, Thomas DJ, Marshall J: Assessment of cerebral haemodynamic reserve: correlation between PET parameters and CO2 reactivity measured by the intravenous 133xenon injection technique. *J Neurol Neurosurg Psychiatr* 51: 1045–1050, 1988

17) Pindzola RR, Sashin D, Nemoto EM, Kuwabara H, Wilson JW, Yonas H: Identifying regions of compromised hemodynamics in symptomatic carotid occlusion by cerebrovascular reactivity and oxygen extraction fraction. *Neural Res* 28: 149–154, 2006

18) Powers WJ, Clarke WR, Grubb RL, Videen TO, Adams HP, Derdeyn CP, COSS Investigators: Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial. *JAMA* 306: 1983–1992, 2011

19) Carlson AP, Yonas H, Chang YF, Nemoto EM: Failure of cerebral hemodynamic selection in general or of specific positron emission tomography methodology?: Carotid Occlusion Surgery Study (COSS). *Stroke* 42: 3637–3639, 2011

**Appendix: Study Organization**

**Principal investigator**
Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan: Susumu Miyamoto, MD, PhD

**Statistical analysis and higher brain function analysis**
Department of Behavioral Neurology and Cognitive Neuroscience, Tohoku University Graduate School of Medicine, Sendai, Japan: Etsuro Mori, MD, PhD

**Safety monitoring committee**
Department of Clinical Neuroscience & Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan: Masayasu Matsumoto, MD, PhD
President, National Hospital Organization, Tokyo, Japan: Takaaki Kirino, MD, PhD

**Diagnostic imaging committee**
Department of Neurosurgery, Iwate Medical University School of Medicine, Morioka, Japan: Kuniaki Ogasawara, MD, PhD
Takeda Oncologic Positron Imaging Center, Kyoto, Japan: Kohei Hayashida, MD
Integrative Stroke Imaging Center, National Cerebral and Cardiovascular Center, Suita, Japan: Jyoji Nakagawara, MD, PhD

**Executive office**
Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan: Koji Ihara, MD, PhD
Department of Neurosurgery, National Cerebral and Cardiovascular Center, Suita, Japan: Jun C. Takahashi MD, PhD and Hiroharu Kataoka, MD, PhD

**Contributing researchers**
Integrative Stroke Imaging Center, National Cerebral and Cardiovascular Center, Suita, Japan: Jyoji Nakagawara, MD, PhD
President, Iwate Medical University School of Medicine, Morioka, Japan: Akira Ogawa, MD, PhD
Department of Behavioral Neurology and Cognitive Neuroscience, Tohoku University Graduate School of Medicine, Sendai, Japan: Etsuro Mori, MD, PhD
President, Tohoku University Graduate School of Medicine, Sendai, Japan: Teiji Tominaga, MD, PhD
Department of Neurosurgery, Tokyo Women’s Medical University, Tokyo, Japan: Yoshikazu Okada, MD, PhD
President, Nara Prefectural Hospital Organization, Yamato-Koriyama, Japan, Toshisuke Sakaki, MD, PhD
Department of Neurosurgery, Tokushima University, Tokushima, Japan: Shinji Nagahiro, MD, PhD
Department of Neurosurgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan: Tooru Inoue, MD, PhD
Chairman, Kokura Memorial Hospital, Kitakyushu, Japan: Izumi Nagata, MD, PhD

Participating centers and researchers
Nakamura Memorial Hospital, Sapporo, Japan: Jyoji Nakagawara and Kazuya Sako
Hokkaido University Graduate School of Medicine, Sapporo, Japan: Tatsuya Ishikawa, Satoshi Kuroda and Fumio Moriwaka
Sapporo Medical University, Sapporo, Japan: Kiyohiro Houkin
Iwate Medical University School of Medicine, Iwate, Japan: Akira Ogawa, Kunikachi Ogasawara and Yasuo Terayama
Research Institute for Brain and Blood Vessels, Akita, Akita, Japan: Akifumi Suzuki, Junta Moroi, and Ken Nagata
Tohoku University Graduate School of Medicine, Sendai, Japan: Tetsuo Tominaga and Etsuro Mori
Kohnan Hospital, Sendai, Miyagi, Japan: Hiroaki Shimizu and Hiroshi Nomura
Nagaoka Chuo General Hospital, Nagaoka, Japan: Shigekazu Takeuchi and Tsukasa Ohno
Niigata Prefectural Shibata Hospital, Niigata, Japan: Tsunenori Ozawa and Takeo Kureso
Chiba Cerebral and Cardiovascular Center, Chiba, Japan: Junichi Ono and Shinji Matsuda
Tokyo Women's Medical University, Tokyo, Japan: Yoshikazu Okada and Shinichiro Uchihama
Tokyo Metropolitan Toshima Hospital, Tokyo, Japan: Mitsuru Seida and Masayoshi Iwakami
National Hospital Organization Kanazawa Medical Center, Kanazawa, Japan: Kiyonobu Ikeda and Eishun Nitta
Nagoya City University Medical School, Nagoya, Japan: Kazuo Yamada and Kosei Ojika

Gifu University Graduate School of Medicine, Gifu, Japan: Toru Iwama and Yuji Tanaka
Kyoto University Graduate School of Medicine, Kyoto, Japan: Nobuo Hashimoto, Keisuke Yamada and Hidenao Fukuyama
National Cerebral and Cardiovascular Center, Suita, Japan: Susumu Miyamoto, Koji Iihara, and Kazuo Minematsu
Nara Medical University, Kashihara, Japan: Toshihiko Sakaki, Hiroyuki Nakase, Syoichiro Kawaguchi, and Junichi Yamao
Tokushima University, Tokushima, Japan: Shinji Nagahiro and Shunya Nakane
Kurashiki Central Hospital, Kurashiki, Japan: Sen Yamagata and Satoshi Yamao
Chugoku Rosai Hospital, Kure, Japan: Kanji Yamane and Satoshi Kataoka
Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan: Shioichi Kato, Michiyasu Suzuki, and Kiyoshi Negoro
National Hospital Organization Kyusyu Medical Center, Fukuoka, Japan: Tooru Inoue and Yasushi Okada
Nagasaki University Medical School, Nagasaki, Japan: Izumi Nagata

Participating centers that registered no cases
Kameda General Hospital, Kamogawa, Japan
University of Yamanashi, Faculty of Medicine, Chuo, Japan
Japan Community Healthcare Organization, Chukyo Hospital, Nagoya, Japan
Hiroshima University, Hiroshima, Japan
Shimane Prefectural Central Hospital, Izumo, Japan

Address reprint requests to: Susumu Miyamoto, MD, PhD, Department of Neurosurgery, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyoku, Kyoto 606-8507, Japan.
e-mail: miy@kuhp.kyoto-u.ac.jp